GEN29 - Pilot Data on Medication Use in Bicuspid Valve Patients

OBJECTIVE: To collect initial cross-sectional data that can serve as pilot data describing current medications and diameters in a cohort of bicuspid aortic valve patients with aortopathy for RCT design

ORGANIZATION

Lead Investigator: Craig Broberg, MD

Co-Investigators: Cheryl Maslen, PhD

Funding Source: GenTAC

BACKGROUND AND RATIONALE

Although the association between aortic enlargement and bicuspid aortic valve is well known, including a higher risk of aortic dissection, there are no data on how to best treat the enlarged aorta in this setting. A randomized controlled trial will be needed to address the efficacy of pharmacotherapy for an enlarged aorta in the setting of a bicuspid aortic valve.

DESIGN

Hypothesis
- A large proportion of patients with bicuspid aortic valves will be taking either a beta blocker or an angiotensin receptor blocker. Those with increased diameters or history of hypertension or coarctation will be more likely to be taking these medications. Medication use may vary by center.

Inclusion criteria:
- All subjects diagnosed with a bicuspid aortic valve.

Exclusion Criteria
- Patients with other familial conditions such as Marfan syndrome, Ehlers-Danlos syndrome, or Loeys-Dietz syndrome.

Samples
- None

Data
- Surgical, imaging and genetics data. Demographics, family history and medication use.

CONCLUSIONS

Results:
- *Results pending*